Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 7/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.40 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL530149 | 0.89 | USP30 (0.44) | GFERKMT2ARAB9A | |
| SCHEMBL659493 | 0.83 | RHOA (0.48) | GFERKMT2AGAAPLA2G1BATG4B | |
| SCHEMBL530349 | 0.80 | SYK (0.49) | — | |
| SCHEMBL660848 | 0.80 | ROCK2 (0.61) | — | |
| SCHEMBL660005 | 0.78 | RXRA (0.52) | GFERKMT2AGAARAB9A | |
| SCHEMBL15080271 | 0.78 | CHEK1 (0.37) | GAARAB9A | |
| SCHEMBL530369 | 0.78 | SYK (0.43) | — | |
| SCHEMBL15328941 | 0.76 | POLB (0.34) | GAARAB9A | |
| SCHEMBL12557711 | 0.76 | POLB (0.34) | GAARAB9A | |
| SCHEMBL530691 | 0.75 | ROCK2 (0.56) | GFERKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604218-B2 | Cytoskeletal active rho kinase inhibitor compounds, composition and use | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-8604205-B2 | Cytoskeletal active rho kinase inhibitor compounds, composition and use | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| EP-2597953-A1 | METHOD FOR TREATING OPHTHALMIC DISEASES USING KINASE INHIBITOR COMPOUNDS IN PRODRUG FORMS | Inspire Pharmaceuticals, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| US-20130131059-A1 | METHOD FOR TREATING OPHTHALMIC DISEASES USING KINASE INHIBITOR COMPOUNDS IN PRODRUG FORMS | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130012543-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | MERCK SHARP & DOHME LLC | 2013-01-10 | — | — | US | disclosed |
| US-20120046275-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | MERCK SHARP & DOHME LLC | 2012-02-23 | — | — | US | disclosed |
| WO-2012015760-A1 | METHOD FOR TREATING OPHTHALMIC DISEASES USING KINASE INHIBITOR COMPOUNDS IN PRODRUG FORMS | INSPIRE PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
| US-8071779-B2 | reduces intraocular pressure; primary open-angle glaucoma; effective to influence the actomyosin interactions by leading to cellular relaxation and alterations in cell-substratum adhesions | INSPIRE PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| EP-2099457-A2 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | Inspire Pharmaceuticals, Inc. (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20080214614-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | MERCK SHARP & DOHME LLC | 2008-09-04 | — | — | US | disclosed |
| WO-2008077057-A2 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | INSPIRE PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131059-A1 | METHOD FOR TREATING OPHTHALMIC DISEASES USING KINASE INHIBITOR COMPOUNDS IN PRODRUG FORMS | ROCK1, ROCK2, CIT | GFER 1950/4885KMT2A 2550/4885GAA 1158/4885 |
| US-20130012543-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | ROCK1, RHOA, ROCK2 | GFER 2259/4885KMT2A 2573/4885GAA 2623/4885 |
| US-20120046275-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | ROCK1, RHOA, ROCK2 | GFER 2259/4885KMT2A 2573/4885GAA 2623/4885 |
| US-20080214614-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | ROCK1, RHOA, ROCK2 | GFER 2259/4885KMT2A 2573/4885GAA 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.